Immunotherapy Scientist, Peter MacCallum Cancer Centre
| Role | Organisation | Sources |
|---|---|---|
| BEAT Inventor (former) | Currus Biologics | Brandon BioCatalyst, Main Sequence |
| Immunotherapy Scientist (former) | Peter MacCallum Cancer Centre | Brandon BioCatalyst, Main Sequence |
Stories naming Dr Clare Slaney. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.
Main Sequence explains why it backed Currus Biologics, whose BEAT platform aims to make CAR-T cell therapies effective against solid tumours, starting with mesothelin-positive cancers, as the team prepares for a clinical trial.